Product Details
PMS-Erlotinib
Erlotinib150 mg
Tablet
DIN/PIN/NPN
02454394
Manufacturer
Pharmascience Inc.
Formulary Listing Date
2016-09-29
Unit Price
71.2000
Amount MOH Pays
71.2000
Coverage Status
Off-Formulary Interchangeable Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
L01EB02
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02377713 | Teva-Erlotinib | 71.2000 | 71.2000 |
02269023 | Tarceva | NA | NA |
02454394 | PMS-Erlotinib | 71.2000 | 71.2000 |
02483939 | Nat-Erlotinib | 71.2000 | 71.2000 |
02461889 | Apo-Erlotinib | 71.2000 | 71.2000 |
LU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Oncology Drugs | Erlotinib
For the treatment of clinically documented incurable progressive non-small cell lung cancer (NSCLC) where:
Patients should be assessed for disease status at least every two months. Erlotinib should be discontinued if there is evidence of disease progression. Note that erlotinib is not indicated and therefore, is not considered for reimbursement as 1st line therapy in treatment of NSCLC. Requests for 2nd-line and 3rd-line use of erlotinib in patients 70 years of age or older and have not received treatment with either platinum-based combinations will be considered on a case-by-case basis. Approved dosage: 150 mg/day Duration of Approval: 6 Months Renewal will be considered for patients who respond to therapy with no evidence of disease progression. Patients should be assessed for disease status at least every two months. Erlotinib should be discontinued if there is evidence of disease progression. Duration of Approval: 6 Months EAP Drug Request Form: |